Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Men with Early-Stage Prostate Cancer Could Delay Treatment In Favour Of Disease Monitoring

XTALKS VITALS NEWS

Prostate Cancer

Active surveillance uses regular physical exams, blood tests and biopsies to determine whether a prostate tumor is progressing before treatment options are considered.

Share this!

October 25, 2016 | by Sarah Hand, M.Sc.

A new report found that over half of the 32,518 Swedish men diagnosed with prostate cancer over a five-year period, chose to monitor their disease as opposed to opting for radiation therapy or surgery. The study – which was published in the journal, JAMA Oncology – suggests that active monitoring could be a safe choice for American prostate cancer patients as well.

Active surveillance uses regular physical exams, blood tests and biopsies to determine whether a prostate tumor is progressing before treatment options are considered. According to the researchers, low-risk patients can avoid treatment-associated side effects – including bowel and bladder incontinence as well as sexual dysfunction – by deciding to actively monitor their disease.

“The main conclusion here is that if the majority of men in Sweden have adopted this management strategy for very low- to low-risk prostate cancer, then more American men might choose this option if it were presented to them,” said lead study author Dr. Stacy Loeb, a urologist at NYU Langone Medical Center. Loeb and her colleagues collaborated with an international team of researchers to complete the study.



Between 2009 and 2014, the researchers found that the incidence of active surveillance among Swedish men diagnosed with very low-risk prostate cancer increased, from 57 to 91 percent. Similarly, in 2014, 74 percent of men with low-risk cancer chose this option, which was up from 40 percent in 2009.

What’s more, the percentage of men who chose the most passive option called watchful waiting, whereby patients forgo further testing and treatment until symptoms develop, decreased by over 50 percent. To complete the study, the researchers used data from Sweden's National Prostate Cancer Register, a unique database with no current US equivalent.

“Our findings should encourage physicians and cancer care professionals in the United States to offer such close supervision and monitoring to their patients with low-risk disease,” said Loeb. “[Increased adoption of active surveillance] could go a long way toward reducing the harms of screening by minimizing overtreatment of non-aggressive prostate cancer.”

A recent study also showed no difference in mortality between men who chose active surveillance and those that chose treatment. According to Loeb, some men who chose to treat their early-stage prostate cancer have later regretted their decision because of long-lasting side effects.


Keywords: Prostate Cancer, Blood Test, Biopsy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News


Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News


Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets from #AAIC17

REGISTER FOR THESE WEBINARS

Into the Great Wide Open: PTC’s Transformation & Global Journey to Bring Patients a First Ever Rare Disease Therapy


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.